Mondelez International, Inc. (NASDAQ:MDLZ) shares decreased -2.94% in last trading session and ended the day at $41.90. MDLZ Gross Margin is 38.80% and its has a return on assets of 11.70%. Mondelez International, Inc. (NASDAQ:MDLZ) quarterly performance is 4.34%.
Mondelez International, Inc. (NASDAQ:MDLZ) announced the launch of a strategic e-commerce partnership with Alibaba Group, the largest online and mobile commerce company in the world. The collaboration enables Mondelēz International to further tap into the potential of e-commerce by expanding its reach and deepening its penetration in the Chinese market.
Memorial Resource Development Corp. (NASDAQ:MRD) ended the last trading day at $12.89. Company weekly volatility is calculated as 5.14% and price to cash ratio as 1199.12. Memorial Resource Development Corp. (NASDAQ:MRD) showed a weekly performance of 1.26%.
Memorial Resource Development Corp. (NASDAQ:MRD) announced that it will report first quarter 2016 financial and operating results before the market opens for trading on May 10, 2016.
On 21 April, Ingredion Incorporated (NYSE:INGR) shares decreased -1.72% and was closed at $104.75. INGR EPS growth in last 5 year was 20.10%. Ingredion Incorporated (NYSE:INGR) year to date (YTD) performance is 9.76%.
Ingredion Incorporated (NYSE:INGR) will release its 2016 first-quarter financial results for the period ended March 31, 2016, before the market opens on Thursday, April 28, 2016.
Endo International plc (NASDAQ:ENDP) shares increased 12.00% in last trading session and ended the day at $31.83. ENDP Gross Margin is 36.50% and its has a return on assets of -8.40%. Endo International plc (NASDAQ:ENDP) quarterly performance is -43.53%.
Zacks Investment Research raised shares of Endo International plc (NASDAQ:ENDP) from a “hold” rating to a “buy” rating and set a $66.00 price objective for the company in a research note on Wednesday
Arbutus Biopharma Corporation (NASDAQ:ABUS) caters to the Healthcare space. Its weekly performance is 2.23%. On the last day of trading company shares ended up at $5.05. Arbutus Biopharma Corporation (NASDAQ:ABUS) distance from 50-day simple moving average (SMA50) is 10.80%.
Arbutus Biopharma Corporation (NASDAQ:ABUS) announced that Patrick T. Higgins, Arbutus’ Chief Business Officer has decided to leave the company at the end of April 2016. Mr. Higgins will continue to be involved with the company. He remains a shareholder of Arbutus and is committed to seeing Arbutus complete its vision of developing a cure for HBV. Mr. Higgins was a co-founder and CEO of OnCore BioPharma, which merged with Tekmira Pharmaceuticals in 2015 to form what is now Arbutus Biopharma.
Leave a Reply